Personal History:I am an Associate Professsor in the Department of Microbial Pathogenesis in the Dental School and an Adjunct Associate Professor in the School of Medicine. In the Fall of 2008, I moved my laboratory from the University of Washington, Seattle, WA where I was a Research Associate Professor in the Department of Medicine, Division of Allergy and Infectious Diseases and a principal investigator with the Northwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (NWRCE) to the University of Maryland - Baltimore. I received my B.S. from the State University of New York at Oswego (biology and chemistry), a M.A. from SUNY Buffalo (Microbiology), and a Ph.D. from the University of Virginia (Microbiology) studying retroviral RNA transport, where I was also a fellow in the Myles H. Thaler Center for Retrovirus Research. Subsequently, I was a senior fellow at University of Washington in the laboratory of Samuel I. Miller (Allergy and Infectious Diseases) from 1997 – 2002 before joining the faculty in 2002.
Research Interests:The focus of our laboratory is to understand the molecular basis by which gram-negative bacteria modify the lipid A component of lipopolysaccharide (LPS) and how these alterations affect or circumvent normal host innate immune system responses. LPS is the major surface molecule and pathogenic factor of Gram-negative bacteria. It consists of three distinct structural regions: O-antigen, core, and lipid A. The molecular structure of LPS varies dramatically among different bacterial species. Gram-negative bacteria have evolved mechanisms to regulate the structure of their LPS during growth in various environmental conditions. During infections of animal hosts, recognition of LPS structures by the host innate immune system promotes the synthesis and secretion of two classes of immune response effectors: cytokines and chemokines that coordinate immune cell responses such as phagocytosis, and anrimicrobial molecules, which directly kill invading microbes. Lipid A, also as known as endotoxin, is recognized by the mammalian innate immune system via the Toll-like receptor 4 (TLR4) complex. Diversity in TLR4-mediated recognition and signaling pathways has been identified across species, and genetic variability in these pathways among individuals may be responsible for clinical variability in infectious disease outcome.
Lipid A structures isolated from different bacterial species vary in the number and length of fatty acid side chains, the presence of terminal phosphate moieties, and other structural modifications. These modifications can promote resistance to host innate immune killing mechanisms by antimicrobial compounds and alter recognition by TLR4. Increasing evidence indicates that selective pressure on both pathogen and host results in the observed diversity of lipid A structures, and that this diversity likely plays a role in the evolution of infectious diseases. Therefore, studying lipid A structural diversity among a variety of Gram-negative species that cause both acute and chronic infections will lead to a better understanding of the molecular mechanism of lipid A recognition by host receptors. Ultimately, these studies may potentially contribute to the development of new antimicrobials that enhance innate immunity or inhibit bacterial resistance, and to the generation of new adjuvants that enable safer, more effective vaccines.
Links of Interest:Visit My Lab
Faculty members: Update your contact information and create a profile.